No Data
No Data
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
Novo Nordisk Says Oral Version of Wegovy Accepted for FDA Review
The FDA Action Date To Decide On The Wegovy Oral Formulation NDA Will Be In Q4 2025
FDA Accepts Filing Application for Oral Semaglutide 25 Mg, Which If Approved, Would Be the First Oral GLP-1 Treatment for Obesity
Why Is Novo Nordisk Stock Trading Higher On Friday?
Sector Update: Health Care Stocks Higher Friday Afternoon